肝细胞癌新辅助治疗的临床方案探讨及未来展望  

Exploration and future prospects of clinical strategies for neoadjuvant therapy of hepatocellular carcinoma

作　　者：宿宇皓 梁宇鑫 钟德源 尚进 黄孝伦[2] SU Yuhao;LIANG Yuxin;ZHONG Deyuan;SHANG Jin;HUANG Xiaolun(School of Medicine,University of Electronic Science and Technology of China,Chengdu 610054,P.R.China;Department of Hepatobiliary and Pancreatic Surgery,Liver Transplantation Center,Sichuan Cancer Hospital,Affiliated Cancer Hospital,University of Electronic Science and Technology of China,Chengdu 610041,P.R.China)

机构地区：[1]电子科技大学医学院,成都610054 [2]电子科技大学附属肿瘤医院,四川省肿瘤医院肝脏移植中心肝胆胰外科,成都610041

出　　处：《中国普外基础与临床杂志》2025年第3期389-396,共8页Chinese Journal of Bases and Clinics In General Surgery

摘　　要：目的总结肝细胞癌新辅助治疗的临床方案并展望其未来前景。方法以“肝细胞癌”“新辅助治疗”“介入治疗”“放射治疗”“靶向治疗”“免疫治疗”等关键词,在中国知网、万方、维普、Pubmed等数据库中检索近5年肝细胞癌新辅助治疗的相关文献并加以综述。结果肝细胞癌的新辅助治疗包括:新辅助介入治疗、放射治疗、靶向治疗、免疫治疗等。新辅助介入治疗和放射治疗对于肝细胞癌伴有门静脉癌栓的患者有显著优势,而新辅助靶向治疗和免疫治疗在肿瘤病理缓解率等方面初见成效,为可切除肝细胞癌患者的诊疗提供了更多思路。结论新辅助治疗是肝细胞癌的新兴治疗手段,已经在临床应用中展现出巨大潜力,并朝着个体化、精准化和系统化的方向迈进。随着对肝细胞癌免疫治疗机制的深入研究和不断的临床实践,以免疫治疗为基础的综合治疗策略将成为未来肝细胞癌新辅助治疗的关键。Objective To explore the clinical protocols of neoadjuvant therapy for hepatocellular carcinoma and to provide a perspective on its future prospects.Method Literature search and review were conducted in CNKI,Wanfang,VIP,PubMed and other databases using keywords such as“hepatocellular carcinoma”,“neoadjuvant therapy”,“interventional therapy”,“radiotherapy”,“targeted therapy”,“immunotherapy”,etc in recent five years.Results Neoadjuvant therapy for hepatocellular carcinoma included neoadjuvant interventional therapy,radiotherapy,targeted therapy,and immunotherapy.Neoadjuvant interventional therapy and radiotherapy had significant advantages for hepatocellular carcinoma patients with portal vein tumor thrombus,while neoadjuvant targeted therapy and immunotherapy had achieved initial results in tumor pathological remission rate,providing more ideas for the diagnosis and treatment of patients with resectable hepatocellular carcinoma.Conclusions Neoadjuvant therapy is an emerging treatment for hepatocellular carcinoma,which has shown great potential in clinical applications and is moving towards individualization,precision,and systematization.We believe that with in-depth research on the mechanism of immunotherapy for hepatocellular carcinoma and continuous clinical practice,a comprehensive treatment strategy based on immunotherapy will become the key to neoadjuvant therapy for hepatocellular carcinoma in the future.

关 键 词：肝细胞癌 新辅助治疗 放射治疗 免疫治疗 

分 类 号：R73[医药卫生—肿瘤]